https://www.army.mil/article/262786/84_million_contract_awarded_for_excalibur_replenishment
Summit Therapeutics Announces Updated Phase II Data For Ivonescimab At 42nd Annual J.P. Morgan Healthcare Conference
Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC PatientsPhase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC PatientsCatalyst Events Expected in Q2 2024 for Two Randomized Phase III Trials Evaluating
